File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome.

TitleUse of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome.
Authors
Issue Date2003
Citation
American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation, 2003, v. 42 n. 5, p. E13-15 How to Cite?
AbstractThe authors report a case of adult-onset minimal change nephrotic syndrome (MCNS) that was resistant to steroid and cyclophosphamide therapy. Introduction of cyclosporin induced an usual cutaneous reaction of severe flushing attacks. Tacrolimus successfully alleviated both the nephrotic syndrome and the cutaneous side effect associated with cyclosporin use. The antiproteinuric mechanisms of tacrolimus and its potential in treating refractory MCNS and other forms of primary glomerulonephritides are discussed.
Persistent Identifierhttp://hdl.handle.net/10722/162857
ISSN
2015 SCImago Journal Rankings: 2.313

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_US
dc.contributor.authorTang, AWen_US
dc.contributor.authorTam, MKen_US
dc.contributor.authorHo, YWen_US
dc.date.accessioned2012-09-05T05:24:29Z-
dc.date.available2012-09-05T05:24:29Z-
dc.date.issued2003en_US
dc.identifier.citationAmerican Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation, 2003, v. 42 n. 5, p. E13-15en_US
dc.identifier.issn1523-6838en_US
dc.identifier.urihttp://hdl.handle.net/10722/162857-
dc.description.abstractThe authors report a case of adult-onset minimal change nephrotic syndrome (MCNS) that was resistant to steroid and cyclophosphamide therapy. Introduction of cyclosporin induced an usual cutaneous reaction of severe flushing attacks. Tacrolimus successfully alleviated both the nephrotic syndrome and the cutaneous side effect associated with cyclosporin use. The antiproteinuric mechanisms of tacrolimus and its potential in treating refractory MCNS and other forms of primary glomerulonephritides are discussed.en_US
dc.languageengen_US
dc.relation.ispartofAmerican journal of kidney diseases : the official journal of the National Kidney Foundationen_US
dc.subject.meshAnti-Inflammatory Agents - Therapeutic Useen_US
dc.subject.meshCyclophosphamide - Therapeutic Useen_US
dc.subject.meshCyclosporine - Adverse Effectsen_US
dc.subject.meshDrug Eruptions - Etiologyen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshFemaleen_US
dc.subject.meshFlushing - Chemically Induceden_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNephrosis, Lipoid - Drug Therapyen_US
dc.subject.meshPrednisolone - Therapeutic Useen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshSteroids - Therapeutic Useen_US
dc.subject.meshTacrolimus - Therapeutic Useen_US
dc.titleUse of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome.en_US
dc.typeArticleen_US
dc.identifier.emailTang, S:scwtang@hku.hken_US
dc.identifier.authorityTang, S=rp00480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid14582073-
dc.identifier.scopuseid_2-s2.0-2142715860en_US
dc.identifier.hkuros95914-
dc.identifier.volume42en_US
dc.identifier.issue5en_US
dc.identifier.spageE13en_US
dc.identifier.epage15en_US
dc.identifier.scopusauthoridTang, S=7403437082en_US
dc.identifier.scopusauthoridTang, AW=7201845919en_US
dc.identifier.scopusauthoridTam, MK=7102267597en_US
dc.identifier.scopusauthoridHo, YW=7402555047en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats